318 related articles for article (PubMed ID: 34322136)
1. Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission?
Hsu DC; Mellors JW; Vasan S
Front Immunol; 2021; 12():710044. PubMed ID: 34322136
[TBL] [Abstract][Full Text] [Related]
2. A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex.
Mishra N; Sharma S; Dobhal A; Kumar S; Chawla H; Singh R; Das BK; Kabra SK; Lodha R; Luthra K
J Virol; 2020 Sep; 94(19):. PubMed ID: 32669335
[TBL] [Abstract][Full Text] [Related]
3. The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention.
Thavarajah JJ; Hønge BL; Wejse CM
Viruses; 2024 Jun; 16(6):. PubMed ID: 38932203
[TBL] [Abstract][Full Text] [Related]
4. Broadly neutralizing antibodies for the treatment and prevention of HIV infection.
Caskey M
Curr Opin HIV AIDS; 2020 Jan; 15(1):49-55. PubMed ID: 31764199
[TBL] [Abstract][Full Text] [Related]
5. Strategies for eliciting multiple lineages of broadly neutralizing antibodies to HIV by vaccination.
Mu Z; Haynes BF; Cain DW
Curr Opin Virol; 2021 Dec; 51():172-178. PubMed ID: 34742037
[TBL] [Abstract][Full Text] [Related]
6. Systematic Assessment of Antiviral Potency, Breadth, and Synergy of Triple Broadly Neutralizing Antibody Combinations against Simian-Human Immunodeficiency Viruses.
Berendam SJ; Styles TM; Morgan-Asiedu PK; Tenney D; Kumar A; Obregon-Perko V; Bar KJ; Saunders KO; Santra S; De Paris K; Tomaras GD; Chahroudi A; Permar SR; Amara RR; Fouda GG
J Virol; 2021 Jan; 95(3):. PubMed ID: 33177194
[TBL] [Abstract][Full Text] [Related]
7. Broadly Neutralizing Antibodies for HIV-1 Prevention.
Walsh SR; Seaman MS
Front Immunol; 2021; 12():712122. PubMed ID: 34354713
[TBL] [Abstract][Full Text] [Related]
8. Broadly neutralizing antibody and the HIV reservoir in acute HIV infection: a strategy toward HIV remission?
Ananworanich J; McSteen B; Robb ML
Curr Opin HIV AIDS; 2015 May; 10(3):198-206. PubMed ID: 25700203
[TBL] [Abstract][Full Text] [Related]
9. The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infection-study protocol for a two-stage randomised phase II trial.
Lee MJ; Collins S; Babalis D; Johnson N; Falaschetti E; Prevost AT; Ashraf A; Jacob M; Cole T; Hurley L; Pace M; Ogbe A; Khan M; Zacharopoulou P; Brown H; Sutherland E; Box H; Fox J; Deeks S; Horowitz J; Nussenzweig MC; Caskey M; Frater J; Fidler S
Trials; 2022 Apr; 23(1):263. PubMed ID: 35382844
[TBL] [Abstract][Full Text] [Related]
10. Single-Chain Variable Fragments of Broadly Neutralizing Antibodies Prevent HIV Cell-Cell Transmission.
van Dorsten RT; Reh L; Trkola A; Morris L; Moore PL
J Virol; 2022 Feb; 96(4):e0193421. PubMed ID: 34935437
[TBL] [Abstract][Full Text] [Related]
11. Adeno-Associated Viral Vector Mediated Expression of Broadly- Neutralizing Antibodies Against HIV-Hitting a Fast-Moving Target.
Sherpa C; Le Grice SFJ
Curr HIV Res; 2020; 18(2):114-131. PubMed ID: 32039686
[TBL] [Abstract][Full Text] [Related]
12. Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection.
Cohen YZ; Caskey M
Curr Opin HIV AIDS; 2018 Jul; 13(4):366-373. PubMed ID: 29697469
[TBL] [Abstract][Full Text] [Related]
13. Broadly neutralizing antibodies combined with latency-reversing agents or immune modulators as strategy for HIV-1 remission.
Gunst JD; Højen JF; Søgaard OS
Curr Opin HIV AIDS; 2020 Sep; 15(5):309-315. PubMed ID: 32675575
[TBL] [Abstract][Full Text] [Related]
14. An HIV-1 Broadly Neutralizing Antibody from a Clade C-Infected Pediatric Elite Neutralizer Potently Neutralizes the Contemporaneous and Autologous Evolving Viruses.
Kumar S; Panda H; Makhdoomi MA; Mishra N; Safdari HA; Chawla H; Aggarwal H; Reddy ES; Lodha R; Kumar Kabra S; Chandele A; Dutta S; Luthra K
J Virol; 2019 Feb; 93(4):. PubMed ID: 30429339
[TBL] [Abstract][Full Text] [Related]
15. Broadly neutralizing antibodies for HIV treatment and cure approaches.
Frattari GS; Caskey M; Søgaard OS
Curr Opin HIV AIDS; 2023 Jul; 18(4):157-163. PubMed ID: 37144579
[TBL] [Abstract][Full Text] [Related]
16. Distinct Immunoglobulin Fc Glycosylation Patterns Are Associated with Disease Nonprogression and Broadly Neutralizing Antibody Responses in Children with HIV Infection.
Muenchhoff M; Chung AW; Roider J; Dugast AS; Richardson S; Kløverpris H; Leslie A; Ndung'u T; Moore P; Alter G; Goulder PJR
mSphere; 2020 Dec; 5(6):. PubMed ID: 33361123
[TBL] [Abstract][Full Text] [Related]
17. Contribution to HIV Prevention and Treatment by Antibody-Mediated Effector Function and Advances in Broadly Neutralizing Antibody Delivery by Vectored Immunoprophylaxis.
Phelps M; Balazs AB
Front Immunol; 2021; 12():734304. PubMed ID: 34603314
[TBL] [Abstract][Full Text] [Related]
18. CD8 Effector T Cells Function Synergistically With Broadly Neutralizing Antibodies to Enhance Suppression of HIV Infection.
Veenhuis RT; Garliss CC; Bailey JR; Blankson JN
Front Immunol; 2021; 12():708355. PubMed ID: 34394110
[TBL] [Abstract][Full Text] [Related]
19. Vaccinal effect of HIV-1 antibody therapy.
Naranjo-Gomez M; Pelegrin M
Curr Opin HIV AIDS; 2019 Jul; 14(4):325-333. PubMed ID: 30973419
[TBL] [Abstract][Full Text] [Related]
20. To bnAb or Not to bnAb: Defining Broadly Neutralising Antibodies Against HIV-1.
Griffith SA; McCoy LE
Front Immunol; 2021; 12():708227. PubMed ID: 34737737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
